Richard K Burt MD
Dr Burt (www.astemcelljourney.com) is a Fulbright Scholar, Professor of Medicine at Scripps Health Care, tenured retired Professor of Medicine at Northwestern University, and director of Genani Corp. He endeavored for 35 years, first with animal models then with some of the world’s first clinical trials, to bring the field of stem cell and cellular therapy to the patient’s bedside. Dr Burt has published more than 145 mostly first author articles and is the Editor of four medical textbooks. He was the first Autoimmune Committee Chairperson for the International Bone Marrow Transplant Registry (IBMTR) and was the principal investigator of a National Institute of Health (NIH) $10,000,000.00 multi-center contract to develop stem cell clinical trials for autoimmune diseases. Professor Burt performed America’s first hematopoietic stem cell transplant (HSCT) for multiple sclerosis (MS), systemic lupus erythematosus (SLE), Crohn’s disease (CD), stiff person syndrome (SPS), and chronic inflammatory demyelinating polyneuropathy (CIDP) and published the world’s first randomized clinical stem cell transplantation trials for systemic sclerosis and multiple sclerosis. He has been awarded Leukemia Scholar of America, the Lupus Foundation of America Fidelitas Award, the Van Bekkum Award by the European Society for Blood and Marrow Transplantation, the Distinguished Clinical Achievement Award by the Clinical Research Forum, and the European Group for Blood and Marrow Transplantation Clinical Achievement Award. Dr Burt was presented in Vatican City, Rome with the “Keys to the Vatican”, was speaker at the Festival of Thinkers in Leadership in Healthcare in the United Arab Emirates, and chaired the biotechnology session at the Baku Azerbaijan International Humanitarian Forum. Dr. Burt was recognized by Science Illustrated for accomplishing one of the Top 10 medical breakthroughs for the next 10 years, and by Scientific American as one of the Top 50 individuals, teams, or organizations for improving humanity and outstanding leadership.